A trial of ASA404 and docetaxel for non small cell lung cancer that has continued to grow during chemotherapy or has come back after treatment (ATTRACT 2)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Lung cancer
Non small cell lung cancer

Status:

Results

Phase:

Phase 3

This trial was looking at a drug called ASA404 in combination with the chemotherapy drug docetaxel for non small cell lung cancer (NSCLC) that was stage 3B or 4.

Doctors often use chemotherapy to treat NSCLC that is locally advanced Open a glossary item or has spread to another part of the body. If NSCLC continues to grow, or comes back after treatment, you may have more chemotherapy. Docetaxel is a drug that doctors may use.

Cancer cells need a blood supply to help them grow and survive. Growing cancer cells can encourage the growth of new blood vessels. This is called angiogenesis.

In this trial, researchers were looking at a drug called ASA404 which targets the cancer’s blood supply and might have helped to stop the cancer growing. They compared ASA404 with a dummy drug (a placebo Open a glossary item). The aims of the trial were to

  • Find out if ASA404 worked better than the dummy drug, when you have it with docetaxel for NSCLC that had continued to grow during chemotherapy or had come back after treatment
  • Learn more about the side effects and how they affected people’s quality of life

Summary of results

The trial recruited 920 people who had non small cell lung cancer that was stage 3B or stage 4. Everybody taking part had already had chemotherapy, but their cancer had continued to grow or had come back after treatment.

  • 460 people had docetaxel and ASA404
  • 460 people had docetaxel and a dummy drug (placebo)

The researchers found that

  • The number of people whose cancer responded to the treatment was about the same in both groups
  • On average, the length of time people lived after treatment was about the same in both groups
  • The side effects were also similar in both groups

The trial team concluded that in this study, ASA404 did not work any better than the dummy drug and the trial was stopped early. There will not be any further trials planned for this drug.

We have based this summary on information from the team who ran the trial.  As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed Open a glossary item) or published in a medical journal yet. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Rohit Lal

Supported by

Novartis

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 3310

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think